[2016年更新 - 尿路上皮癌的免疫疗法]
[Update 2016 - Immunotherapy for urothelial carcinoma].
作者信息
Retz M, Gschwend J E, Schmid S C
机构信息
Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland.
出版信息
Urologe A. 2016 Feb;55(2):246-52. doi: 10.1007/s00120-015-0024-y.
Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.
晚期膀胱尿路上皮癌是一种侵袭性肿瘤，预后较差。除手术治疗外，含铂化合物的经典化疗是晚期膀胱癌治疗的主要方法。近年来，免疫调节疗法已成为临床试验的焦点。本综述概述了目前正在临床试验中分析的生物学机制和免疫肿瘤学药物以及既定的标准疗法。
Zotero 插件